Are the antimicrobial properties of macrolides required for their therapeutic efficacy in chronic neutrophilic airway diseases?

Brusselle, Guy G

doi:10.1136/thoraxjnl-2015-207080

Cited by 9 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data evaluating azithromycin consists of retrospective studies and small prospective trials. Overall, this data suggests that azithromycin may contribute to stabilization of lung function and improvement in FEV1, with some studies demonstrating a reduction in the incidence of CLAD (119)(120)(121)(122)(123)(124)(125)(126)(127)(128)(129)(130)(131)(132). In a randomized, double-blind, placebo-controlled trial, Vos et al randomized 83 patients to azithromycin or placebo and found that those treated with azithromycin had lower rates of BOS (12.5% vs. 44.2%, P=0.0017), improved FEV1, and lower airway neutrophilia.…”

Section: Adjunctive Therapiesmentioning

confidence: 79%

Immunosuppression in lung transplantation: a narrative review

Atkinson¹,

Sharma²

2023

Curr Chall Thorac Surg

View full text Add to dashboard Cite

Background and Objective: Lung transplantation has grown as a treatment option for patients with end stage lung disease. Unfortunately, median survival for lung transplant recipients remains low at 6.7 years. Acute rejection and chronic lung allograft dysfunction (CLAD) are among the main challenges to graft function and overall survival. Immunosuppression is utilized to reduce the rate of rejection, and can be utilized as a treatment for acute rejection and CLAD. The purpose of this review is to describe the immunosuppressive agents used in lung transplantation for induction therapy, maintenance therapy, and prevention of both acute and chronic allograft rejection.Methods: PubMed was searched using keywords including "lung transplantation, immunosuppression, induction, maintenance" from January 1985 to June 2022. Systematic reviews, randomized clinical trials, retrospective and cross-sectional studies, case series, and some animal studies were considered for inclusion in this review, with no language restrictions.

show abstract

Section: Adjunctive Therapiesmentioning

confidence: 79%

Immunosuppression in lung transplantation: a narrative review

Atkinson¹,

Sharma²

2023

Curr Chall Thorac Surg

View full text Add to dashboard Cite

show abstract

“…Macrolides may be of benefit in asthma despite the fact that their administration may increase the risk for microbial resistance. They achieve their action through different mechanisms which are mainly related to either an anti-inflammatory effect or/and to their possible inhibitory effect on the microbiome and virobiome within the airways [ 73 ]. Only two studies have examined their clinical effect on severe asthma.…”

Section: Treating Severe Asthma: Current Optionsmentioning

confidence: 99%

“…Only two studies have examined their clinical effect on severe asthma. The study by B russelle [ 73 ] investigated whether the administration of low-dose azithromycin in patients with severe asthma could potentially alter the rate of exacerbations during a period of 6 months follow-up. The study was considered negative since it failed to reach the primary outcome.…”

Section: Treating Severe Asthma: Current Optionsmentioning

confidence: 99%

An algorithmic approach for the treatment of severe uncontrolled asthma

et al. 2018

View full text Add to dashboard Cite

A small subgroup of patients with asthma suffers from severe disease that is either partially controlled or uncontrolled despite intensive, guideline-based treatment. These patients have significantly impaired quality of life and although they constitute <5% of all asthma patients, they are responsible for more than half of asthma-related healthcare costs. Here, we review a definition for severe asthma and present all therapeutic options currently available for these severe asthma patients. Moreover, we suggest a specific algorithmic treatment approach for the management of severe, difficult-to-treat asthma based on specific phenotype characteristics and biomarkers. The diagnosis and management of severe asthma requires specialised experience, time and effort to comprehend the needs and expectations of each individual patient and incorporate those as well as his/her specific phenotype characteristics into the management planning. Although some new treatment options are currently available for these patients, there is still a need for further research into severe asthma and yet more treatment options.

show abstract

“…In the (very unlikely) event that the overlap of asthma and bronchiectasis in the same individual were considered a new disease entity, we would present our eponym candidate to join the eminent list of doctors who helped to discover these diseases, as well as famous persons who suffered from them. Hence the Serrano-Soriano Syndrome (or the other way around) would hopefully help to identify new avenues for research, especially including those therapeutic measures that can simultaneously improve the control of both diseases, such as the treatment of airways inflammation (either with inhaled steroids [26] or macrolides [27]) or immunoglobulin replacement [28]. We will keep wondering if Laennec's stethoscope (figure 1) and other tools will help to disentangle the overlap of asthma and bronchiectasis.…”

mentioning

confidence: 99%